[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endometrial-high-grade-endometrioid-adenocarcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endometrial-high-grade-endometrioid-adenocarcinoma":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100597709","molecular-and-ctdna-characterization-of-high-risk-endometrial-cancer-100597709",false,"NCT07062016","Molecular and ctDNA Characterization of High-Risk Endometrial Cancer","MC230601 Molecular and ctDNA Characterization of High-Risk Endometrial Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Planned complete surgical staging at Mayo Clinic. Complete surgical staging includes at least total hysterectomy, bilateral salpingo-oophorectomy and lymph node assessment. Sentinel node mapping meets the criteria for lymph node assessment. Peritoneal cytology is recommended. Additional staging procedures such as pelvic and para-aortic nodal evaluation, omental biopsy or omentectomy, may also be utilized for staging in patients based on the clinical situation and at the surgeon's discretion\n* At least one preoperative or postoperative feature of aggressive disease \\[International Federation of Gynecology and Obstetrics (FIGO) staging used throughout this protocol\\]\n\n  * Preoperatively:\n\n    * Biopsy with grade 3 endometrioid endometrial cancer (EC) or non-endometrioid EC\n    * Patients with FIGO grade 1-2 EC with evidence of extrauterine disease on imaging (CT, MRI, or PET)\n  * Postoperatively:\n\n    * Endometrial cancer (FIGO) with one or more established risk factors:\n\n      * Non-endometrioid histology\n\n        * Grade 3\n      * Lymphovascular space invasion (LVSI), ≥ 50% of myometrial invasion, presence of isolated tumor cells (ITC) in a sentinel lymph node OR\n      * Stage II to IV (FIGO) EC\n* Provide written informed consent\n* Willingness to provide mandatory blood specimens for correlative research\n* Willingness to provide mandatory tissue specimens for correlative research\n* Willingness to return to registering site for clinical follow-up\n\nExclusion Criteria:\n\n* Patient receiving or who has received neoadjuvant chemotherapy\n* Pre-operative pregnancy","FEMALE","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","This study seeks to better understand the recurrence of high-risk endometrial cancer. It will collect information about cancer genetics to find out various hereditary or cancer specific genetic variants that may have a role in diagnosis or management and prognosis of cancer. It also seeks to develop a genetic results and medical record databank for future studies.",[24,25,26,27,28],"Endometrial Carcinoma","Endometrial High Grade Endometrioid Adenocarcinoma","Stage II Endometrial Cancer","Stage III Endometrial Cancer","Stage IV Endometrial Cancer","RECRUITING","2026-04-09",{"date":32,"type":33},"2026-04-13","ACTUAL",{"date":35,"type":33},"2025-10-01",{"date":37,"type":20},"2028-10-31",{"name":39,"class":40},"Mayo Clinic","OTHER"]